Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

19.6%

18 terminated/withdrawn out of 92 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

37%

34 trials in Phase 3/4

Results Transparency

62%

39 of 63 completed trials have results

Key Signals

7 recruiting39 with results15 terminated

Enrollment Performance

Analytics

Phase 2

28(35.0%)

Phase 4

20(25.0%)

Phase 3

14(17.5%)

N/A

10(12.5%)

Phase 1

6(7.5%)

Early Phase 1

2(2.5%)

80Total

Phase 2(28)

Phase 4(20)

Phase 3(14)

N/A(10)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (92)

Showing 20 of 92 trials

NCT06917313Phase 2Recruiting

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Role: collaborator

NCT05239624Phase 2Recruiting

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Role: collaborator

NCT05756777Phase 1Recruiting

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Role: collaborator

NCT06891560Phase 2Recruiting

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Role: collaborator

NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Role: collaborator

NCT06099769Phase 2Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Role: collaborator

NCT05868265Phase 2Recruiting

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Role: collaborator

NCT02749903Phase 2Active Not Recruiting

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Role: collaborator

NCT03149055Phase 2Completed

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Role: collaborator

NCT01489176Phase 3Completed

Regadenoson Real Time Perfusion Imaging Trial-Optison

Role: collaborator

NCT02099864Phase 2Completed

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Role: collaborator

NCT00868621Completed

Urinary Cytokines in Patients With Overactive Bladder (OAB)

Role: collaborator

NCT00839540Phase 4Completed

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

Role: collaborator

NCT00743197Not ApplicableTerminated

Women With Chest Pain and Normal Coronary Arteries Study

Role: collaborator

NCT01949337Phase 3Unknown

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Role: collaborator

NCT00905515Phase 4Completed

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

Role: collaborator

NCT01094691Not ApplicableCompleted

Haufen Diagnostic Biomarkers of BK Renal Disease

Role: collaborator

NCT01026012Not ApplicableCompleted

Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing

Role: collaborator

NCT00852696Not ApplicableTerminated

Over Active Bladder Patients Having Sling Surgery

Role: collaborator

NCT00727090Phase 4Terminated

Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

Role: collaborator